NextCure, Inc. (NXTC)

On our desk, NXTC is heavily impacted by the terms of the Avere reverse merger. With current holders keeping only about 1.21% of the combined AVRX entity, retail sentiment has turned sharply defensive. We are monitoring the legal scrutiny from Halper Sadeh LLC very closely because class action or disclosure challenges could delay the transaction timeline outlined in the Form 425 and S-4 filings.

Watching the 50-day moving average near $3.35 and the recent quote around $1.97, the technical picture reflects extreme erosion. The company reported a Q2 net loss of $14.9 million ($2.80 per share, missing consensus estimates by $0.85) on zero product revenue. With cash down to $20.1 million and operations only funded into Q4 2026, management is explicitly preserving capital just to cross the finish line of this merger.

From a clinical transition perspective, our team is tracking how legacy oncology assets are being spun off into Contingent Value Rights (CVRs). Shareholders are slated to receive CVRs for 90% of any net proceeds from monetizing NextCure’s legacy pipeline over the two years post-closing. Valuing these CVRs requires discounting trial failures against potential licensing agreements, but right now the market is ascribing almost zero value to them.

As a hedge fund PM, the proposed structure involves a complex two-step reverse merger where Neptune Merger Sub Corp merges into Avere, followed immediately by Avere merging into Neptune Second Merger Sub, LLC. The massive scale of Avere's private placement syndicates—pegged between $320 million and $500 million in concurrent capital—means existing NXTC equity is effectively being wiped out to accommodate a private-to-public backdoor listing for Avere's oral IL-23 therapy.

On our options desk, implied volatility on NXTC is pricing in a binary event around the upcoming Form S-4 registration statement and proxy vote. With a market capitalization hovering between $7.22 million and $21 million depending on daily volume spikes, liquidity is thin, and retail order flow can spark sharp 15% intraday jumps on zero fundamental revenue news before fading right back down.